Pregnant or breast-feeding females
Pregnant or breast feeding females.
Pregnant or breast feeding females.
Pregnant or breast feeding females.
Females who are pregnant or breast feeding are excluded since there are unknown teratogenic effects of these agents
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking the study drugs)
Pregnant or breast-feeding females
Female subject is pregnant or breast-feeding; lactating females must agree not to breastfeed while taking lenalidomide
Pregnant or breast feeding females
Pregnant or breast-feeding females are excluded
Females who are pregnant or breast-feeding
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide).
Pregnant or breast-feeding females
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast-feeding females
Females who are pregnant or breast-feeding
Pregnant or breast-feeding females.
Pregnant or breast-feeding females.
Pregnant or breast feeding females
Pregnant or breast-feeding females
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Pregnant or breast feeding females are excluded
Pregnant and breast-feeding females
Pregnant or breast feeding females
Pregnant or breast-feeding females are excluded
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females
Pregnant or breast feeding females
Breast feeding females
Females who are pregnant or breast-feeding
Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide)
Relapsed/refractory MCL: Pregnant or breast feeding females
Pregnant or breast-feeding females; lactating females must agree not to breast-feed while taking lenalidomide
Females who are pregnant or breast-feeding
Pregnant or breast-feeding females
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
Females who are pregnant or breast-feeding.
Pregnant or breast feeding females.
Pregnant or breast-feeding females
Pregnant or breast-feeding females
Females who are pregnant or breast-feeding
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast-feeding females
Non pregnant, non-breast feeding females under active contraception
Pregnant or breast-feeding females or females who intend to become pregnant during study participation.
Pregnant or breast-feeding females
Pregnant or breast-feeding females
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast-feeding females
Females must not be pregnant or breast-feeding
Pregnant or breast-feeding females
Females who are pregnant or breast feeding are not eligible for this study
Females who are breast-feeding or pregnant
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast feeding females
Pregnant or breast-feeding females; patients who become pregnant during active therapy will be immediately removed from the study
Females who are pregnant or breast-feeding
Pregnant or breast feeding females
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide)
Breast feeding females
Females who are pregnant or breast feeding
Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
Both men and women may be enrolled; premenopausal females must have a negative pregnancy test prior to treatment and lactating females will have to discontinue breast feeding to be eligible
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females.
Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
Pregnant or breast feeding females.(Lactating females must agree not to breast feed while taking lenalidomide).
Lactating or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast feeding females are not eligible
Females who are pregnant or breast-feeding
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking Revlimid)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide or azacitidine)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Females who are pregnant or are breast-feeding.
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
For females, if they are pregnant or breast-feeding
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking ibrutinib or idelalisib)
Females who are breast-feeding or pregnant
Pregnant or breast feeding females
Breast feeding or pregnant females
Breast feeding or pregnant females
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Breast feeding females
Pregnant or breast-feeding females
Pregnant or breast-feeding females.
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant, lactating or actively breast feeding females.
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking ipilimumab)
Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
Breast feeding females
Lactating females who are actively breast feeding.
Pregnant or breast-feeding females
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast-feeding females
Females who are pregnant or might be pregnant or are breast-feeding
Pregnancy or failure to use effective contraception in fertile males or females, and breast-feeding females
Females who are pregnant or breast feeding
Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
Pregnant or breast feeding females
Pregnant or breast feeding females
Pregnancy/breast feeding: females who are pregnant or breast feeding at the time of study entry are not eligible
Pregnant or breast-feeding females
Pregnant or lactating females
Since the teratogenic potential of this combination is currently unknown, females who are pregnant or lactating are excluded. Males and females should perform abstinence or use barrier to prevent pregnancy.
Pregnant or lactating females
Pregnant or lactating females.
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females are excluded
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Lactating females and/or pregnant females
Pregnant or lactating females.
Pregnant females; (lactating females must agree not to breast feed while taking ibrutinib)
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Females who are pregnant or lactating
Pregnant or lactating females
Pregnant or lactating females
Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
PART 1 EXCLUSION CRITERIA: Pregnant or lactating females
PART 2 GROUP 1 EXCLUSION CRITERIA: Pregnant or lactating females
PART 2 GROUP 2A EXCLUSION CRITERIA: Pregnant or lactating females
PART 2 GROUP 3 EXCLUSION CRITERIA: Pregnant or lactating females
Females who are pregnant, lactating, or intend to become pregnant during the participation of the study
Pregnant or lactating females
Females who are pregnant or lactating
Females who are pregnant or lactating
Pregnant or lactating females
Pregnant or lactating females
DONOR: Lactating females
Lactating females
DONOR: Females must not be pregnant or lactating
Pregnant or lactating female: all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment; lactating females must discontinue breast feeding
Lactating females
Females who are pregnant or lactating
Lactating females
Lactating females
Pregnant or lactating females
No pregnant or lactating females
Patients must not be pregnant or lactating females.
Lactating females
Pregnant or lactating females
Pregnant or lactating females
Lactating females
Pregnant or lactating females
Lactating or pregnant females
Pregnant females; (lactating females must agree not to breast feed while taking the study medications)
Pregnant or lactating females
Women who are pregnant or lactating due to potential exposure of the fetus to RT and unknown effects of RT to lactating females
Pregnant and lactating females will be excluded
Pregnant or lactating females
Lactating females
Lactating females must agree to discontinue nursing
Females who are pregnant or lactating or plan to become pregnant during the course of this study.
Pregnant or lactating females
Lactating females.
Pregnant or lactating females
Lactating females
Pregnant or lactating females
Lactating females
Pregnant or lactating females
Lactating or pregnant females
Lactating females are not eligible
DONOR: Pregnant or lactating females
Pregnant or lactating females who chose to breast feed
Pregnant or lactating females
Lactating or pregnant females
Lactating females
Lactating or pregnant females
Pregnant or lactating females.
Females who are pregnant or lactating.
Unrelated Donor: Pregnant or lactating females
Pregnant or lactating (breastfeeding) females.
DONOR: Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females.
Lactating females
Pregnant or lactating females
Females who are pregnant or lactating
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant females (lactating females must agree not to breast feed while taking carfilzomib, lenalidomide or romidepsin)
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
No pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females.
Pregnant or lactating females
Pregnant or lactating females
Lactating females
Pregnant or lactating females
Lactating females
Pregnant or lactating females
Pregnant females; (lactating females must agree not to breastfeed while taking lenalidomide or romidepsin)
Pregnant or lactating females
Pregnant or lactating females
Females who are pregnant or lactating
DONOR: Pregnant or lactating females
Females who are pregnant or lactating
Pregnancy or lactating females
Pregnant or lactating females.
Females who are pregnant or lactating.
Pregnant or lactating females
Pregnant or lactating females.
Pregnant or lactating females.
Lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Male or non-pregnant, non-lactating, females
Pregnant or lactating females
Pregnant or lactating females
Suspected pregnancy, pregnant or lactating females
Females who are pregnant or lactating
Pregnant or lactating females
Pregnant, lactating or breastfeeding females
Lactating females or pregnant females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females.
Pregnant or lactating females.
Pregnant or lactating females
Females who are pregnant or lactating
Pregnant or lactating females are excluded from enrollment on this trial
Females who are pregnant or lactating
Pregnant or lactating females
Pregnant or lactating females
Pregnant or lactating females
HEALTHY VOLUNTEER: Females who are pregnant or nursing or are actively lactating
Pregnant or lactating females
Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate.
Females who are pregnant and/or lactating
Females who are lactating or pregnant.
Pregnant or lactating females
Female patients who are pregnant or breast-feeding
Female patients who are lactating must agree to stop breast-feeding
Current pregnancy or breast feeding; pregnant women are excluded from this study; breastfeeding should be\r\ndiscontinued in all female subjects
Female patients who are pregnant (per institutional practice) or breast-feeding.
Female patients who are pregnant or are breast feeding.
Females of child-bearing potential cannot be pregnant or breast-feeding; female participants >= 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment; female participants who are breast feeding must agree to stop breast feeding
A female patient who is pregnant or breast-feeding
Female subjects who are pregnant or breast-feeding
Female patients who are pregnant or breast feeding are not eligible
Female patients who are pregnant or breast-feeding
If female, is pregnant or is breast feeding.
Female participants of child-bearing potential cannot be pregnant or breast-feeding
Female patients who are lactating must agree to stop breast feeding
Female patients who are lactating must agree to stop breast-feeding
Pregnant or breast feeding (female of child-bearing potential)
If female, subject is pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Female patients who are breast-feeding.
Female patients should not be pregnant or breast?feeding
Female patients must not be pregnant or breast-feeding
Be female and pregnant or breast feeding.
Female patients who are pregnant or breast feeding
Female patients who are pregnant or breast-feeding
Female who is pregnant or breast feeding and HCV treatment requires use of ribavirin
Pregnant or breast feeding female patient
Female participant who is pregnant or breast-feeding
Female participants who are lactating, breast feeding, or pregnant.
Female patients who are pregnant or breast feeding are not eligible
Female subjects who are pregnant or breast feeding
Female patients who are pregnant or breast-feeding, or intends to become pregnant during the study
Female subject is pregnant or breast-feeding
A female patient who is pregnant or breast-feeding
Female participants pregnant or breast-feeding
If female, patient is pregnant or breast-feeding.
Pregnant or breast-feeding female patients;
Patients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in female patients who are postmenarchal
Pregnant or breast-feeding female patients
Female patients who are lactating must agree to stop breast-feeding
Female participants pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Female patients who are pregnant or breast feeding
Female patient pregnant or breast feeding
Breast feeding (Female only)
DONOR: Breast feeding (Female only)
Female patients who are pregnant or breast-feeding
Female participants who were breast feeding or pregnant.
Female subject is pregnant or breast-feeding
Female patients who are pregnant or breast feeding
Female patients who are pregnant or breast-feeding
Female patients who are pregnant or breast feeding
Female subject is pregnant or breast-feeding.
Pregnant or breast-feeding female
Female participants who are breast-feeding
Female patients who are pregnant or breast feeding
If female, is pregnant or breast-feeding;
Female participants who are pregnant, lactating, or breast-feeding
If female, is lactating or breast feeding
Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
Female patients who are lactating must agree to stop breast-feeding
Female patients who are pregnant or breast-feeding
Pregnant and/or breast feeding if a female recipient
(Female only) Breast feeding
Female patients who are pregnant or breast feeding
Female subjects must not be pregnant or breast feeding within 6 months prior to and during course of study
Female patients cannot be pregnant or breast feeding
Female pregnant or breast feeding
Pregnant or breast feeding female patient
